Clinical Trials
26 trialsNCT06161025 2026-05-22
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Daiichi Sankyo
Phase 2/3 Recruiting
NCT07219238 2026-05-05
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
GE Healthcare
Phase 2/3 Recruiting
NCT02839707 2026-05-04
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT02502266 2026-04-29
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT07550205 2026-04-24
Tiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian Cancer
Shanghai Municipal Hospital of Traditional Chinese Medicine
Phase 2/3 Not yet recruiting
NCT07472140 2026-03-16
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
N.N. Alexandrov National Cancer Centre
Phase 2/3 Recruiting
NCT07109414 2026-03-09
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
Novita Pharmaceuticals, Inc.
Phase 2/3 Active not recruiting
NCT07440290 2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3 Not yet recruiting
NCT06851663 2025-12-08
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital
Phase 2/3 Recruiting
NCT05786716 2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05870748 2025-09-23
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sutro Biopharma, Inc.
Phase 2/3 Terminated
NCT03755739 2024-06-25
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 2/3 Recruiting
NCT06211023 2024-01-18
A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2/3 Not yet recruiting
NCT03458221 2023-04-18
STAPOVER
Gynaecologisch Oncologisch Centrum Zuid
Phase 2/3 Recruiting
NCT04795596 2022-04-15
Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers
Menoufia University
Phase 2/3 Withdrawn
NCT02490488 2020-12-08
Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients
AB Science
Phase 2/3 Completed
NCT04055038 2019-08-13
EPITOC
Blokhin's Russian Cancer Research Center
Phase 2/3 Unknown
NCT00443196 2018-03-12
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
Pierian Biosciences
Phase 2/3 Completed
NCT01196741 2015-05-05
SaPPrOC
University College, London
Phase 2/3 Completed
NCT00003880 2015-04-16
Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT00075712 2013-08-12
Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT00045461 2013-08-07
Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2/3 Unknown
NCT00327444 2013-01-01
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
Sanofi
Phase 2/3 Completed
NCT00243685 2012-01-26
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
Pierian Biosciences
Phase 2/3 Completed
NCT00418574 2011-11-24
MIMOSA
Menarini Group
Phase 2/3 Terminated